Table 3.

Post-treatment measurement associations with overall by reader (time 0 = end of treatment date)

Variable	R1			R2
	N(#Events)	HR (95% CI)	p-value	N(#Events)	HR (95% CI)	p-value
PostTx total size	85 (54)	1.15 (1.07–1.24)	< 0.001	84 (53)	1.13 (1.05–1.22) 0.002	0.002
L1 PostTx APHE	85 (54)		< 0.001	85 (54)		0.001
Present	32 (25)	Ref.		38 (28)	Ref.
Not present	53 (29)	0.36 (0.20–0.63)		47 (26)	0.38 (0.21–0.69)
L1 PostTx WO	85 (54)		< 0.001	85 (54)		< 0.001
Present	22 (18)	Ref.		30 (23)	Ref.
Not present	63 (36)	0.32 (0.18–0.57)		55 (31)	0.34 (0.19–0.60)
L1 PostTx ESTPT	85 (54)		< 0.001	85 (54)		0.002
Not present	57 (32)	Ref.		51 (29)	Ref.
Present	28 (22)	2.78 (1.61–4.78)		34 (25)	2.43 (1.37–4.30)
L1 PostTx LR-TR category	85 (54)		0.001	84 (53)		0.003
Non-viable	51 (28)	Ref.		36 (18)	Ref.
Equivocal	8 (5)	2.47 (0.92–6.61)		13 (6)	1.40 (0.55–3.62)
Viable	26 (21)	3.08 (1.68–5.63)		35 (29)	2.81 (1.54–5.15)
L2 PostTx LR-TR category	14 (8)		0.38	14 (8)		0.76
Non-viable	8 (4)	Ref.		9 (5)	Ref.
Equivocal	3 (2)	1.55 (0.25–9.74)			0.00 (0.00–.)
Viable	3 (2)	3.99 (0.58–27.59)		4 (3)	1.77 (0.38–8.17)
Summary PostTx LR-TR category	85 (54)		0.002	84 (53)		0.006
Non-viable	50 (27)	Ref.		37 (19)	Ref.
Equivocal	9 (6)	1.78 (0.73–4.38)		13 (6)	1.32 (0.52–3.39)
Viable	26 (21)	2.98 (1.64–5.45)		34 (28)	2.57 (1.41–4.67)

Abbreviations: APHE, nonrim-like enhancement in the arterial phase; ESTPT, enhancement similar to pre-treatment; HR, Hazard Ratio; Tx, treatment; L1, lesion 1; L2, lesion 2; LR-TR, LI-RADS treatment response; WO, washout